These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22666496)

  • 21. Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Lloyd SM; Stott DJ; de Craen AJ; Kearney PM; Sattar N; Perry I; Packard CJ; Briggs A; Marchbank L; Comber H; Jukema JW; Westendorp RG; Trompet S; Buckley BM; Ford I
    PLoS One; 2013; 8(9):e72642. PubMed ID: 24023757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly.
    Polisecki E; Peter I; Simon JS; Hegele RA; Robertson M; Ford I; Shepherd J; Packard C; Jukema JW; de Craen AJ; Westendorp RG; Buckley BM; Schaefer EJ;
    J Lipid Res; 2010 May; 51(5):1201-7. PubMed ID: 19752398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study.
    Iakoubova OA; Robertson M; Tong CH; Rowland CM; Catanese JJ; Blauw GJ; Jukema JW; Murphy MB; Devlin JJ; Ford I; Shepherd J
    Eur J Cardiovasc Prev Rehabil; 2010 Aug; 17(4):455-61. PubMed ID: 20215968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical relevance of statins: their role in secondary prevention.
    Tonkin AM
    Atheroscler Suppl; 2001 Feb; 2(1):21-5. PubMed ID: 11286152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Common genetic variants do not predict recurrent events in coronary heart disease patients.
    Thompson PL; Hui J; Beilby J; Palmer LJ; Watts GF; West MJ; Kirby A; Marschner S; Simes RJ; Sullivan DR; White HD; Stewart R; Tonkin AM
    BMC Cardiovasc Disord; 2022 Mar; 22(1):96. PubMed ID: 35264114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS).
    Am J Cardiol; 1995 Nov; 76(12):899-905. PubMed ID: 7484829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pravastatin: a review of its use in elderly patients.
    Bang LM; Goa KL
    Drugs Aging; 2003; 20(14):1061-82. PubMed ID: 14651445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS).
    L'Italien G; Ford I; Norrie J; LaPuerta P; Ehreth J; Jackson J; Shepherd J
    Am J Cardiol; 2000 Mar; 85(6):720-4. PubMed ID: 12000046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
    Maitland-van der Zee AH; Boerwinkle E; Arnett DK; Davis BR; Leiendecker-Foster C; Miller MB; Klungel OH; Ford CE; Eckfeldt JH
    Am Heart J; 2007 Jan; 153(1):54-8. PubMed ID: 17174637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
    Simes RJ; Marschner IC; Hunt D; Colquhoun D; Sullivan D; Stewart RA; Hague W; Keech A; Thompson P; White H; Shaw J; Tonkin A;
    Circulation; 2002 Mar; 105(10):1162-9. PubMed ID: 11889008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project.
    Byington RP; Davis BR; Plehn JF; White HD; Baker J; Cobbe SM; Shepherd J
    Circulation; 2001 Jan; 103(3):387-92. PubMed ID: 11157690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preventing the next event in the elderly: the PROSPER perspective.
    Shepherd J
    Atheroscler Suppl; 2003 Dec; 4(5):17-22. PubMed ID: 14980231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
    Keech A; Colquhoun D; Best J; Kirby A; Simes RJ; Hunt D; Hague W; Beller E; Arulchelvam M; Baker J; Tonkin A;
    Diabetes Care; 2003 Oct; 26(10):2713-21. PubMed ID: 14514569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.
    Lowe G; Rumley A; Norrie J; Ford I; Shepherd J; Cobbe S; Macfarlane P; Packard C
    Thromb Haemost; 2000 Oct; 84(4):553-8. PubMed ID: 11057849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT).
    Koizumi J; Shimizu M; Miyamoto S; Origasa H; Mabuchi H
    J Atheroscler Thromb; 2002; 9(5):251-9. PubMed ID: 12409635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study.
    Brouilette SW; Moore JS; McMahon AD; Thompson JR; Ford I; Shepherd J; Packard CJ; Samani NJ;
    Lancet; 2007 Jan; 369(9556):107-14. PubMed ID: 17223473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease.
    Ledmyr H; McMahon AD; Ehrenborg E; Nielsen LB; Neville M; Lithell H; MacFarlane PW; Packard CJ; Karpe F;
    Circulation; 2004 May; 109(19):2279-84. PubMed ID: 15136504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men.
    Skogsberg J; McMahon AD; Karpe F; Hamsten A; Packard CJ; Ehrenborg E;
    J Intern Med; 2003 Dec; 254(6):597-604. PubMed ID: 14641801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.